|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 12, Num. 2, 1995, pp. 74
|
Revista Biotecnologia Aplicada 12(2): 74 (1995)
REPORTE CORTO/SHORT REPORT
Presented in the Congress Biotecnologia Habana 94. La Habana,
Cuba, Nov. 28 - Dec. 3, 1994
THE Neisseria meningitidis OUTER MEMBRANE PROTEIN P1
PRODUCED IN Bacillus subtilis AND REFOLDED in vitro
AS A VACCINE CANDIDATE.
Pirjo H. Makela, Sarah Butcher, Ilona Idanpan-Heikkila, Marjatta
Nurminen, Susanna Mutilaine, Kate Runeberg-Nyman, Matti Srvas and
Eva Wahistr. National Public Health Institute, Mannerheimintic
166, FIN/00300 Helsinki, Finland.
Code Number: BA95015
File Sizes:
Text: 5K
No associated graphics
INTRODUCTION
Single component vaccine have many advantages: low probability
of adverse reactions and high immunogenicity, with the antibody
response directed to the protective component. It is essential,
however, that the component is chosen correctly and presented in
a form preserving the native three-dimensioned structure of the
epitopes that serve as targets of protective antibodies.
There is definitive clinical need for efficacious vaccines
against Neisseria meningitidis of group B (MenB). Previous
work had established that the capsular polisacharide of MenB is
unlikely to serve as a basic of a vaccine because of its
structural and antigenic similarity with certain glycoproteins
in human tissues (Finne et al., 1983). In order to
identify a potential alternative vaccine component, our
laboratory has developed an experimental animal model for MenB
disease (Saukkonen et al, 1987). In this model we could
show that antibodies to the class 1 protein (P1) of the
meningococcal outer membrane were protective.
Because of the anticipated difficulties in purification of the
P1 protein from MenB, especially in removal of the endotoxin
(LPS) associated with it, we expressed P2 in a heterologous host,
the Gram-positive, therefore LPS-free, Bacillus subtilis
by methods developed in our laboratory (Palva et al.,
1982). The protein, called BacP1, was produced in high yield as
inclusion bodies (Nurminen et al., 1992).
When the protein was solubilised in urea or SDS and to immunize
mice, the antibodies elicited did, however, not bind to
meningococci. We belived that this was due to the denatured
conformation of the protein under these conditions, and procceded
to find ways of refolding it so that native-like epitopes were
fermed. We initially succededin this by refolding in the presence
of LPS (Nurminen et al., 1992). Because of the
undesirability of LPS in a vaccine we then looked for alternative
procedures, and report here that BacP1 can be reconstituted into
phospholipid vesicles (liposomes) which provoke antibodies that
are bactericidal for MenB bacteria and protective in the infant
rat model of meningitis.
EXPERIMENTAL PROCEDURE
BacP1 was expressed in B. subtilis from a bacillar
promoter; the peptide consisted of the precise sequence of the
mature P1 of MenB, precceded at the N terminus by 11 amino acids
encoded by the linker and a truncated bacillar signal sequence
(Nurminen et al., 1992). The protein was solubilized with
SDS, and then diluted into an excess of octylglucoside (OG).
Micelles of phosphatidyl choline were prepared in OG and added,
and the mixture subjected to dialysis or gel filtration. This
procedure led, as expected (Eisele and Rosenbusch, 1990) to the
formation of unilamellar liposomes upon removal liposomes (at
1-20 ug protein/dose, two subcutaneous doses). The sera were
analyzed by enzyme immunoassay (EIA) with denatured BacP1 or
native meningococcal cells (MenB) as antigen. They were also
analyzed for bactericidal activity towards MenB bacteria and for
their ability to confer passive protection in the meningitis
model (Saukkonen et al., 1987).
RESULTS AND DISCUSSION
The liposomes were highly immunogenic without the need of
adjuvants. Analysis of the sera of the immunized mice indicated
the presence of native/like epitopes in the BacP1 in the
liposomes: the reacted to a high titer with native MenB bacterial
both in EIA and bactericidal assays, and were protective in the
experimental infection model. All these reactions were specific
to the subtype of the P1 of the meningococci from which the gene
was derived (P1.7,16 or P1.15), further indicating the formation
of the specific surface epitopes (Van der Ley et al.,
1991).
REFERENCES
EISELE, J. L. et al. (1990). J. Biol. Chem.
265:10217-10220
FINNE et al. (1993). Lancet 11:355-357
NURMINEN, M. S. et al. (1992). Mol. Microbiol.
6(17):2499-2506
PALVA, Y. et al. (1982). Proc. Natl. Acad. Sci.,
USA 79:5582-5586
SAUKKONEN, K. et al. (1987). Microb. Pathogen
3:261-267
VAN der LEY, P. et al. (1991). Infection and
Immunity 59:2963-2971
Copyright 1995 Sociedad Iberolatinoamericana de Biotecnologia
Aplicada a la Salud
|